HAILEY DAVIS: Open Payments
NPI 1104327667 · NEW ALBANY, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$861 in 51 payments from 20 companies in 2025. Trend: 2023 $1,018 · 2024 $842 · 2025 $861
Food & beverage: $861
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $137 |
| Abbott Laboratories | 5 | $101 |
| Novo Nordisk Inc | 6 | $92 |
| Alpha Cognition USA, Inc. | 2 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $54 |
| AstraZeneca Pharmaceuticals LP | 3 | $47 |
| Dexcom, Inc. | 2 | $34 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $30 |
| Amgen Inc. | 2 | $29 |
Products named: REXULTI, Zunveyl, UBRELVY, FREESTYLE LIBRE 3, Kerendia, Ozempic, FREESTYLE LIBRE, QULIPTA.
Industry payments across MS — which companies pay providers there.
